Literature DB >> 2469074

PAP and PSA in prostatic carcinoma cell lines and aspiration biopsies: relation to hormone sensitivity and to cytological grading.

M Hasenson1, B Lundh, R Stege, K Carlström, A Pousette.   

Abstract

Because a change from hormone-sensitive to hormone-resistant carcinoma of the prostate often occurs concomitantly with genetic changes or as a result of the latter, the markers specific for prostatic tissues might also be affected. We therefore first studied the presence of prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA) in LNCaP and LNCaP-r human prostatic carcinoma cell lines. Since both markers were found in these cell lines, we proceeded to quantitate PAP and PSA in aspiration biopsies from patients with prostate tumors. The amounts of these markers were compared with cytological findings. PAP and PSA were analyzed in the biopsy material from 120 patients using commercial radioimmunoassay (RIA) kits. DNA was determined using Riedel H33258 stain. Cytological grading was performed according to the Uropathological Study Group of Prostatic Carcinoma. Significant correlations were found between PAP/DNA or PSA/DNA values and grade of differentiation of the prostate tumor. In view of earlier reports and the results presented here, the amounts of markers or the protein pattern of tumor tissue may be a useful complement to the morphological findings and for selecting optimal therapy for patients with prostatic tumors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2469074     DOI: 10.1002/pros.2990140202

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  4 in total

1.  Molecular analysis and characterization of PrEC, commercially available prostate epithelial cells.

Authors:  Richard E Sobel; Yuzhuo Wang; Marianne D Sadar
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Jan-Feb       Impact factor: 2.416

2.  Serum TPS, PSA, and PAP values in relapsing stage D2 adenocarcinoma of the prostate.

Authors:  I Kraljić; K Kovacić; M Tarle
Journal:  Urol Res       Date:  1994

3.  Can prostate-specific antigen be used as a valid end point to determine the efficacy of chemotherapy for advanced prostate cancer?

Authors:  B Seckin; C T Anthony; B Murphy; M S Steiner
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

4.  Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen.

Authors:  H H Heidtmann; D M Nettelbeck; A Mingels; R Jäger; H G Welker; R E Kontermann
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.